<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02676869</url>
  </required_header>
  <id_info>
    <org_study_id>IMP321-P012</org_study_id>
    <nct_id>NCT02676869</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of IMP321 Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma</brief_title>
  <acronym>TACTI-mel</acronym>
  <official_title>A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Immutep Australia Pty. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Prima BioMed Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Immutep Australia Pty. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and recommended phase 2
      dose of a new drug, known as IMP321, in combination with pembrolizumab when given to patients
      with unresectable or metastatic melanoma.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Study is an open label, dose escalation study. The dose is escalated following the protocol-defined safety observation period of the previous cohort.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment emergent adverse events, serious adverse events and dose limiting toxicities.</measure>
    <time_frame>From the time of inform consent form signature until 30 days after end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events evaluated according to the current National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v4.03)</measure>
    <time_frame>From the time of inform consent form signature until 30 days after end of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate according to RECIST 1.1</measure>
    <time_frame>At 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate according to irRC</measure>
    <time_frame>At 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Stage IV Melanoma</condition>
  <condition>Stage III Melanoma</condition>
  <arm_group>
    <arm_group_label>IMP321 dose escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IMP321 administered fortnightly in addition to SOC pembrolizumab.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMP321</intervention_name>
    <description>Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks</description>
    <arm_group_label>IMP321 dose escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Administered according to the approved label.</description>
    <arm_group_label>IMP321 dose escalation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Able to give written informed consent and to comply with the protocol

          2. Histologically confirmed diagnosis of locally advanced (unresectable Stage III) or
             metastatic (Stage IV) melanoma

          3. Currently receiving anti-PD-1 therapy with pembrolizumab and after 3 cycles achieved
             asymptomatic irPD (slowly progressive, not requiring urgent intervention, and stable
             performance status) or sub-optimal response (irSD, irPR) as demonstrated in imaging
             assessments performed within 6 weeks prior to day 1 of cycle 5 of pembrolizumab.

          4. Female or male 18 years of age or above

          5. All patients with reproductive potential must agree to use effective contraception
             from time of study entry until at least 4 months after the last administration of
             study treatment.

          6. ECOG performance status 0-1

          7. Expected survival longer than three months

          8. Resolution of toxicity associated with prior or current therapy to grade &lt; 2 (except
             for alopecia and transaminases in case of liver metastases)

          9. Evidence of measurable disease as defined by Response Evaluation Criteria in Solid
             Tumours (RECIST) version 1.1

         10. Laboratory criteria:

               -  Absolute neutrophil count &gt; 1.5 x 109/L

               -  Platelet count ≥ 100 x 109/L

               -  Haemoglobin &gt; 9 g/dL or 5.58 mmol/L

               -  Serum creatinine ≤ 1.5 × ULN

               -  Total bilirubin &lt; 20 mmol/L, except for familial cholemia (Gilbert's disease)

               -  Serum AST (=GOT) and ALT (=GPT) &lt; 3 times the upper limit of normal or &lt; 5 times
                  upper limit of normal if liver metastases are present

        Exclusion Criteria

          1. More than four prior lines of therapies for advanced or metastatic disease.

          2. Prior PD-1/PDL-1 targeted therapy

          3. Prior high-dose chemotherapy requiring hematopoietic stem cell rescue

          4. Currently receiving treatment with another investigational drug, or less than 4 weeks
             since ending treatment on another investigational drug

          5. Currently receiving systemic chemotherapy, targeted small molecule therapy,
             radiotherapy, or biological cancer therapy (other than pembrolizumab) or less than 4
             weeks since completion of these therapies and first dose of study treatment

          6. History of irAEs from ipilimumab of CTCAE Grade 4 requiring steroid treatment

          7. Known cerebral or leptomeningeal metastases. (Some subjects with previously treated
             brain metastases may participate under specific circumstances)

          8. Women who are pregnant or lactating

          9. Serious intercurrent infection within 4 weeks prior to first dose of study treatment

         10. Evidence of severe or uncontrolled cardiac disease (NYHA III-IV) within 6 months prior
             to first dose of study treatment

         11. Active acute or chronic infection

         12. History or evidence of interstitial lung disease or active non-infectious pneumonitis

         13. Active auto-immune disease requiring immunosuppressive therapy

         14. HIV positivity

         15. Active hepatitis B or hepatitis C, currently treated with antiviral therapy

         16. Life threatening illness unrelated to cancer

         17. Previous malignancies within the last three years other than melanoma

         18. Any current disorder that would impede the patient's ability to provide informed
             consent or to comply with the protocol

         19. Continuous systemic treatment with either corticosteroids or other immunosuppressive
             medications within 4 weeks prior to first dose of study treatment

         20. History or evidence of severe allergic episodes and/or angioedema

         21. Any current disorder likely to modify absorption, distribution or elimination of
             IMP321

         22. Alcohol or substance abuse disorder

         23. Known hypersensitivity to any of the components of IMP321

         24. Unwilling or unable to follow protocol requirements

         25. In the clinical judgment of the investigator, the patient is unsuitable for
             participation in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prima BioMed</last_name>
    <email>tactimel@primabiomed.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Brisbane Womens Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenslopes Private Hospital</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4120</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Flinders Medical Centre</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5042</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3181</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fiona Stanley Hospital</name>
      <address>
        <city>Perth</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2016</study_first_submitted>
  <study_first_submitted_qc>February 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2016</study_first_posted>
  <last_update_submitted>March 1, 2017</last_update_submitted>
  <last_update_submitted_qc>March 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

